Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual ... Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1 | 2.58397932817 | 3.87 | 4.1299 | 3.6 | 7826 | 3.76805103 | CS |
4 | -0.29 | -6.80751173709 | 4.26 | 4.34 | 3.6 | 7500 | 3.8805644 | CS |
12 | -0.25 | -5.92417061611 | 4.22 | 5.2 | 2.78 | 14079 | 3.76963213 | CS |
26 | -0.24 | -5.70071258907 | 4.21 | 5.2 | 2.78 | 9287 | 3.87189158 | CS |
52 | -1.73 | -30.350877193 | 5.7 | 5.97 | 2.78 | 7057 | 3.88980218 | CS |
156 | -18.13 | -82.036199095 | 22.1 | 24.2 | 2.40101 | 88193 | 12.50306977 | CS |
260 | -10.43 | -72.4305555556 | 14.4 | 56.8 | 2.40101 | 723207 | 26.44248847 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.